Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML

• Published in: The New England journal of medicine Vol. 381; no. 18; pp. 1728 - 1740
• Main Authors: Perl, Alexander E, Martinelli, Giovanni, Cortes, Jorge E, Neubauer, Andreas, Berman, Ellin, Paolini, Stefania, Montesinos, Pau, Baer, Maria R, Larson, Richard A, Ustun, Celalettin, Fabbiano, Francesco, Erba, Harry P, Di Stasi, Antonio, Stuart, Robert, Olin, Rebecca, Kasner, Margaret, Ciceri, Fabio, Chou, Wen-Chien, Podoltsev, Nikolai, Recher, Christian, Yokoyama, Hisayuki, Hosono, Naoko, Yoon, Sung-Soo, Lee, Je-Hwan, Pardee, Timothy, Fathi, Amir T, Liu, Chaofeng, Hasabou, Nahla, Liu, Xuan, Bahceci, Erkut, Levis, Mark J
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 31-10-2019
• Subjects: Acute myeloid leukemia; Administration, Oral; Adult; Aged; Aged, 80 and over; Aniline Compounds - adverse effects; Aniline Compounds - therapeutic use; Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Chemotherapy; Death; Drug Resistance, Neoplasm; Female; Flt3 protein; fms-Like Tyrosine Kinase 3 - genetics; Follow-Up Studies; Humans; Laboratories; Leukemia, Myeloid, Acute - drug therapy; Leukemia, Myeloid, Acute - genetics; Leukemia, Myeloid, Acute - mortality; Liver - drug effects; Male; Medical prognosis; Middle Aged; Mutation; Myeloid leukemia; Neutropenia; Pharmaceuticals; Protein-tyrosine kinase; Pyrazines - adverse effects; Pyrazines - therapeutic use; Recurrence; Remission; Remission (Medicine); Remission Induction; Salvage Therapy; Survival; Survival Analysis; Thrombocytopenia
• ISSN: 0028-4793; 1533-4406
• DOI: 10.1056/NEJMoa1902688

Oral use of the selective FLT3 kinase inhibitor gilteritinib in patients who had relapsed or refractory acute myeloid leukemia with
FLT3
mutations led to a median overall survival of 9.3 months (vs. 5.6 months with standard chemotherapy) and complete remission with full or partial hematologic recovery in 34.0% of patients (vs. 15.3%).